Definium Therapeutics, Inc. (DFTX)
37.80
-2.45
(-6.09%)
USD |
NASDAQ |
Sep 15, 11:07
Definium Therapeutics Enterprise Value : 4.361B for Sept. 14, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 14, 2026 | 4.361B |
| September 11, 2026 | 4.178B |
| September 10, 2026 | 4.022B |
| September 09, 2026 | 4.057B |
| September 08, 2026 | 4.089B |
| September 04, 2026 | 4.071B |
| September 03, 2026 | 4.058B |
| September 02, 2026 | 4.179B |
| September 01, 2026 | 4.126B |
| August 31, 2026 | 4.290B |
| August 28, 2026 | 4.459B |
| August 27, 2026 | 4.841B |
| August 26, 2026 | 4.834B |
| August 25, 2026 | 4.974B |
| August 24, 2026 | 4.767B |
| August 21, 2026 | 4.987B |
| August 20, 2026 | 5.053B |
| August 19, 2026 | 5.109B |
| August 18, 2026 | 5.158B |
| August 17, 2026 | 5.034B |
| August 14, 2026 | 4.681B |
| August 13, 2026 | 4.851B |
| August 12, 2026 | 4.702B |
| August 11, 2026 | 4.450B |
| August 10, 2026 | 5.019B |
| Date | Value |
|---|---|
| August 07, 2026 | 5.152B |
| August 06, 2026 | 5.152B |
| August 05, 2026 | 4.917B |
| August 04, 2026 | 4.639B |
| August 03, 2026 | 4.568B |
| July 31, 2026 | 4.800B |
| July 30, 2026 | 4.931B |
| July 29, 2026 | 4.617B |
| July 28, 2026 | 4.591B |
| July 27, 2026 | 4.683B |
| July 24, 2026 | 4.753B |
| July 23, 2026 | 4.721B |
| July 22, 2026 | 4.820B |
| July 21, 2026 | 5.010B |
| July 20, 2026 | 4.703B |
| July 17, 2026 | 4.904B |
| July 16, 2026 | 4.878B |
| July 15, 2026 | 5.088B |
| July 14, 2026 | 5.131B |
| July 13, 2026 | 4.818B |
| July 10, 2026 | 5.277B |
| July 09, 2026 | 5.463B |
| July 08, 2026 | 5.042B |
| July 07, 2026 | 4.929B |
| July 06, 2026 | 4.909B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cocrystal Pharma, Inc. | 15.23M |
| CNBX Pharmaceuticals, Inc. | 1.305M |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | -11.18M |
| Fulcrum Therapeutics, Inc. | -24.44M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -158.99M |
| Total Expenses (Quarterly) | 158.99M |
| EPS Diluted (Quarterly) | -1.436 |
| Earnings Yield | -9.10% |
| Normalized Earnings Yield | -6.733 |